Pratsinis, Manolis http://orcid.org/0000-0002-1931-0952
Müllhaupt, Gautier
Güsewell, Sabine
Betschart, Patrick
Zumstein, Valentin
Engeler, Daniel
Schmid, Hans-Peter
Lamb, Alastair D.
Abt, Dominik
Funding for this research was provided by:
Blumenau-Léonie-Hartmann Foundation
Article History
Received: 24 August 2022
Accepted: 28 January 2023
First Online: 16 February 2023
Declarations
:
: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: (please list all conflict of interest with the relevant author’s name): Manolis Pratsinis currently receives funding from the Swiss Cancer Research Foundation (BIL KFS-5248-02-2021). He has previously received education support from Janssen Pharmaceutica. Gautier Müllhaupt currently receives funding from Blumenau-Léonie-Hartmann Foundation. Sabine Güsewell has no financial disclosures or conflicts of interest to declare. Patrick Betschart has previously received education support from Janssen Pharmaceutica. Valentin Zumstein has no financial disclosures or conflicts of interest to declare. Daniel Engeler has no financial disclosures or conflicts of interest to declare. Hans-Peter Schmid has no financial disclosures or conflicts of interest to declare. Alastair Lamb currently receives funding from Cancer Research UK (C57899/A25812) and the Oxford NIHR Biomedical Research Centre Surgical Innovation & Evaluation theme. He has previously received grant funding from Prostate Cancer UK (PA14-022), The Academy of Medical Sciences (SGCL11), Medical Research Council (CiC), National Institute of Health Research and GlaxoSmithKline. He has received education support from Astellas, Lilly, AstraZeneca and Ipsen. He is a stipendiary BJUI Section Editor for Prostate Cancer and has received honoraria for reviewing for European Urology and Lancet Oncology. He has received consulting fees from AlphaSights. Domink Abt has no financial disclosures or conflicts of interest to declare.
: All procedures performed involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the local ethics committee (EKOS 21/084).
: Informed consent was obtained from all individual participants included in the study.